Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on June 23, 2017, 10:16:01 am

Title: High Take-Two Cure Rates With Gilead’s New Triple-Drug Hep C Regimen
Post by: Hep Editors on June 23, 2017, 10:16:01 am

Gilead’s experimental fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir cured hepatitis C virus (HCV) at high rates among those who failed a previous treatment for the virus in two recent large trials, MedPage Today reports. The regimen also performed very well among participants with compensated cirrhosis, the less severe stage of the advanced liver disease, which can lower the chance of a cure.

At the end of June, the FDA is expected to decide whether to approve the combination tablet of the NS5B polymerase inhibitor sofosbuvir (brand name Sovaldi), the NS5A inhibitor velpatasvir (when combined with sofosbuvir, this drug is marketed as Epclusa) and the NS3-NS4A protease inhibitor voxilaprevir.

Read more...
https://www.hepmag.com/article/high-taketwo-cure-rates-gileads-new-tripledrug-hep-c-regimen